Glaxo SmithKline executive team announced

Glaxo Wellcome and SmithKline Beecham have announced the make-up of thecorporate executive team that will lead their merged company, Glaxo SmithKline. As previously stated, GW's Sir Richard Sykes will be non-executive chairman, while SB's Jean-Pierre Garner will become chief executive of the new company.

John Coombe (GW) will be chief financial officer; Robert Ingram (GW) becomes chief operating officer and president of pharmaceutical operations; James Niedel (GW) chief science and technology officer; and Tadataka Yamada (SB) will be chairman, R&D.

James Berry (SB) becomes senior vice president and general counsel; George Morrow (GW) and David Stout (SB) will respectively serve as president of the new firm's two US subsidiaries; James Palmer (GW) becomes senior vice president, clinical development; Daniel Phelan (SB) is named vice president human resources; Howard Plen (SB) will be president, pharmaceuticals, international, responsible for all operations outside the USA and Europe, including Japan and Canada; Timothy Tyson (GW) is named president, worldwide manufacturing and supply operations; Chris Viehbacker (GW) is named president, pharmaceuticals Europe; and John Ziegler (SB) will be president, consumer healthcare.